Novo Nordisk in den Nachrichten
Gesundheitslösungen für Diabetes
Tamtam hat 20 aktuelle Artikel über Novo Nordisk gefunden.
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
- Aktien er nede med 22 pct. i år: Her er analytikernes dom over Novo-aktien
- Novo Nordisk introduces new diabetes treatment option in Thailand
- Hackers had access to Novo Nordisk systems for at least 47 days
- Novo goes on deal spree amid semaglutide patent expiries
- QMs samarbejde med Novo Nordisk og Qpurpose
- Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
- Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
- Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
- Novo Nordisk (NVO) Pulls Back Sharply, Is It A Bargain?
- Novo flags FDA hemophilia review extension tied to manufacturing site corrections
- FDA delays decision on Novo's hemophilia drug
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S : JP Morgan is Neutral
- Novo Looks Beyond GLP-1s as Competition Intensifies
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
- Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
- Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- Novo Nordisk (NVO) Stock Looks Reasonable Given Uncertain Long Term Earnings
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Novo Nordisk?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden